Inactivated poliovirus type 1 antigenic epitopes (IPV1 antigen)

Inactivated poliovirus type 1 antigenic epitopes are the specific structural motifs on the surface of the inactivated Mahoney strain of poliovirus that are recognized by the host immune system to elicit a protective response (NIH, 2018). These epitopes are primarily located on the viral capsid proteins VP1, VP2, and VP3, and their immunogenicity is dependent on maintaining the native "D-antigen" conformation during the chemical inactivation process (Ferguson et al., 1993; News-Medical, 2023). In the context of the Inactivated Poliovirus Vaccine (IPV), these epitopes serve as the primary immunogenic components that prime the immune system to produce neutralizing antibodies (GPEI, 2024). These antibodies bind to the virus and prevent it from attaching to the poliovirus receptor (CD155) on host cells, thereby blocking viral entry and systemic spread to the central nervous system (News-Medical, 2023). While IPV is highly effective at preventing paralytic poliomyelitis by inducing systemic humoral immunity, it provides significantly less mucosal immunity in the gastrointestinal tract compared to live-attenuated vaccines (WHO, 2024). Consequently, individuals immunized with these epitopes can still be infected with and shed wild poliovirus, although they remain protected from the disease's paralytic effects (GPEI, 2024).

Other names

Poliovirus type 1 D-antigenMahoney strain antigenIPV type 1 epitopesPoliovirus type 1 capsid proteinsInactivated poliovirus type 1 D-antigen

Induction of humoral immunity through the production of neutralizing antibodies that bind to viral capsid epitopes and prevent infection of host cells.